Abstract
Background Major depressive disorder (MDD) affects a significant portion of the population, with approximately 70% of patients not achieving adequate remission using anti-depressant monotherapy, a condition known as inadequate treatment response (ITR). In the Indian population, few studies have explored the genetic associations of this response, and those that exist are underpowered. This study aims to identify single nucleotide variations associated with ITR in the Indian population. The goal is to develop a population-specific gene panel that can identify subjects at risk for ITR, allowing alternative treatment modalities.
Methods Subjects satisfying inclusion-exclusion criteria were enrolled for the study following institutional ethical approval. We recruited 120 subjects with MDD and assessed their response to monotherapy (Escitalopram) using the Hamilton Depression Rating Scale (HAMD) before and 4-6 weeks after medication. Responders (n=45) and non-responders (n=75) were genotyped using the Infinium Global Screening SNP-Array-24 v3.0. A genome-wide association study (GWAS) was performed to identify SNPs associated with ITR.
Results Twelve lead-significant SNPs with a threshold of < 1E-05 were identified, suggesting an association with ITR. Among these, four SNPs were located in the intronic/regulatory regions of the genes LRSAM1, EFCAB2, TRIM56 and ZNF17. The remaining eight SNPs were near genes ALDH1A2, LIPC, MYOCD, SPRY2, ANKRD18B, CCDC54, TNS3, ANKRD46, and FCRL2. These genes are involved in critical functions related to cell signalling, immune response, neurodevelopment, regulating intracellular levels, and transcription factor binding.
Conclusions Our study identified several novel SNPs that may be associated with ITR in MDD patients, reported for the first time in an Indian cohort. Further investigations are underway to determine their clinical significance and potential to be used for screening individuals responding to drug interventions as user-friendly gene panels.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by ICMR to vide project No. 5/4-4/187/M/2020-NCD-II
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institute Ethics Committee of All India Institute of Medical Sciences, New Delhi gave ethical approval for this work, file no. IEC-523/05.06.2020, RP-16/2020
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 5 was cropped in the previous version and thus revised. Acknowledgments revised, Page no, line no. added.
